#USA #Class Action #Securities Fraud #Radnor #Capricor Therapeutics

Capricor Therapeutics, Inc. and the Class Action Lawsuit

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently embroiled in a significant legal battle, with a class action lawsuit filed against the company due to alleged securities fraud. The laws governing such cases are crucial for investors who might feel wronged by the potential misrepresentations made by company officials regarding their business practices.

The Details of the Lawsuit

According to recent disclosures, the lawsuit targets investors who purchased or acquired Capricor securities within a specified period, from December 17, 2025, to July 26, 2026. The legal action was initiated in the Southern District of California, under the case cited as Darren Ngasseu Nkamga v. Capricor Therapeutics, Inc.

Key Allegations Against Capricor

The lawsuit is founded on claims that the defendants made materially false or misleading statements about Capricor's business operations and prospects. Specifically, the allegations delve into several critical issues:
1. Misrepresentation of the Statistical Analysis Plan: It is asserted that the company failed to disclose changes to the statistical analysis plan for analyzing clinical data concerning its product candidates.
2. FDA Compliance Failure: The company allegedly did not secure the FDA's approval for the revised analysis plan before resubmitting a Biologics License Application (BLA).
3. Consequences of Non-Disclosure: The absence of FDA agreement raised significant risks regarding the clinical results' credibility, risking eventual approval of their lead product.

Stock Price Drop Sparks Concern

The controversy intensified when, on July 27, 2026, the FDA released briefing documents ahead of a crucial advisory committee meeting for Deramiocel's BLA. These documents indicated that Capricor had not followed essential regulatory procedures, particularly regarding the submission of the statistical analysis plan to the FDA. Following the revelation, Capricor's stock plummeted by approximately 64%, prompting even more scrutiny and concern among investors.

Investors' Next Steps

For those who bought Capricor securities and suffered losses, time is of the essence. Investors interested in joining the lawsuit must act by September 28, 2026, to file for lead plaintiff status, which gives them representation in the case. Engaging with legal representation that specializes in securities fraud is vital for navigating these proceedings. Kessler Topaz Meltzer & Check, LLP (KTMC), a prominent law firm known for handling such class actions, is encouraging affected parties to reach out for a consultation at no cost. Their experiences and expertise could facilitate a clearer understanding of the legal landscape ahead.

Understanding the Lead Plaintiff Process

The role of the lead plaintiff is crucial in these class action lawsuits, as this individual or group will represent the interests of all class members. Candidates are typically determined based on the largest financial stakes in the matters at hand. Selecting the right legal representation helps ensure that investors’ rights and potential recoveries are adequately protected throughout the process.

Conclusion

As the lawsuit unfolds, Capricor Therapeutics finds itself at a crossroads that could shape its future and that of its investors. The allegations of securities fraud, if proven, could lead to significant ramifications for the company, however, it is essential for affected investors to stay engaged and proactive during this period. For more information about the class action and their rights, investors are encouraged to consult with legal experts early and often.